Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Convertible Debt (2017 - 2023)

Historic Convertible Debt for Neurocrine Biosciences (NBIX) over the last 6 years, with Q1 2023 value amounting to $169.5 million.

  • Neurocrine Biosciences' Convertible Debt changed N/A to $169.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $169.5 million, marking a year-over-year change of. This contributed to the annual value of $317.9 million for FY2020, which is 2223.58% down from last year.
  • According to the latest figures from Q1 2023, Neurocrine Biosciences' Convertible Debt is $169.5 million.
  • In the past 5 years, Neurocrine Biosciences' Convertible Debt registered a high of $414.1 million during Q1 2020, and its lowest value of $169.5 million during Q1 2023.
  • Moreover, its 4-year median value for Convertible Debt was $362.1 million (2019), whereas its average is $348.5 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Convertible Debt surged by 525.25% in 2020 and then crashed by 2224.1% in 2021.
  • Over the past 4 years, Neurocrine Biosciences' Convertible Debt (Quarter) stood at $408.8 million in 2019, then decreased by 22.24% to $317.9 million in 2020, then increased by 4.03% to $330.7 million in 2021, then tumbled by 48.75% to $169.5 million in 2023.
  • Its last three reported values are $169.5 million in Q1 2023, $330.7 million for Q3 2021, and $326.3 million during Q2 2021.